Different doses of intrathecal dexmedetomidine used as adjuvant to hyperbaric prilocaine

The impact of different doses of intrathecal dexmedetomidine used as adjuvant to hyperbaric prilocaine in short ambulatory procedures under spinal anaesthesia: a randomized controlled study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202204558879194

Enrollment

Registered

2022-04-28

Start date

2021-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

Group A

Group B

Group C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Adult patients (18-65 years). • Both genders • ASA I-II. • Patients scheduled for elective surgeries under spinal anaesthesia.

Exclusion criteria

Exclusion criteria: • Patients with impaired mental status. • Patients with body mass index 35 kg/m2. • Patients suffering from coagulation disorders. • Patients with histories of allergic reactions to local anesthetics or dexmedetomidine. • Patients suffering from severe cardiac, respiratory, hepatic, renal or neuropsychiatric disorders. • Patients with histories of chronic use/abuse of sedatives, narcotics, and of alcohol or other drug abuse.

Design outcomes

Primary

Measure	Time frame
Duration of analgesia pain free interval	—

Secondary

Measure	Time frame
Mean arterial blood pressure;Duration of motor block ;Level of postoperative level of sedation by Ramsay sedation scale	—

Countries

Egypt

Contacts

Public ContactMohamed Zedan

Assisstant Lecturer AFCM

mohammedzedan99@gmail.com01001935006

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026